SEC Form 4 · accession 0001487371-15-000006
GenMark Diagnostics, Inc. · GNMK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hany Massarany
Officer — President and CEO · Director
Period of report
Jan 22, 2015
Accepted (ET)
Jan 26, 2015 · 7:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001487371
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 22, 2015 | M | 10,800 | $0.00 | A | 143,245 | D | |
| Common StockF2 | Jan 22, 2015 | S | 5,982 | $12.88 | D | 132,445 | D | |
| Common StockF2,F3 | holding | — | — | — | 343,597 | I | Massarany Family Trust dated November 15, 2012 |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF4,F5 | — | Jan 22, 2015 | M | 10,800 | D | — | — | Common Stock | 10,800 | 32,400 | D |
Explanation of responses
- F1The shares were sold pursuant to a Rule 10b5-1 trading plan solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units.
- F2The reporting person transferred 4,818 shares of the Issuer's common stock into the Massarany Family Trust dated November 15, 2012 in connection with the applicable restricted stock units vesting event.
- F3Mr. Massarany is the trustee of the Massarany Family Trust and may be deemed to have beneficial ownership of these securities, to the extent of any indirect pecuniary interest in his distributive shares therein.
- F4Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock based on the achievement of particular performance measures.
- F525% of the restricted stock units vest in each of 2014, 2015, 2016 and 2017, in each case based on the achievement of particular product development and commercialization milestones.